Note 2 - Revenue

12 Months Ended

Dec. 31, 2021

Notes to Financial Statements

Revenue from Contract with Customer [Text Block]

Note 2 - Revenue

The Company recorded the following revenues for the years ended December 31:

	2021			2020		2019
Product sales, net:
ORLADEYO	$	121,865		$	133	$	−
RAPIVAB		7,231			483		13,864
Peramivir		7,254			2,685		3,669
Total product sales, net		136,350			3,301		17,533
Royalty revenue		(100	)		3,381		6,303
Milestone revenue		15,000			−		−
Collaborative and other research and development revenues:
U.S. Department of Health and Human Services		5,920			9,231		4,898
Torii Pharmaceutical Co., Ltd.		−			1,899		20,101
Total collaborative and other research and development revenues		5,920			11,130		24,999
Total revenues	$	157,170		$	17,812	$	48,835